Skip to main content

Table 1 Table 1

From: Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study

  T2DM Carvedilol
(N = 9)
T2DM Metoprolol
(N = 10)
Healthy controls
(N = 10)
P Carvedilol vs. metoprolol P Carvedilol vs. control P Metoprolol vs. control
Age (years) 58.9 ± 2.67 58.0 ± 3.02 47.6 ± 1.89 0.83 0.003 0.009
Sex (M/F) 7/2 9/1 5/5    
Smoking (%) 1 (11) 2 (20) 0    
Oral hypoglycaemic* (%) 8 (89) 9 (90) 0    
Aspirin (%) 0 0 0    
Statins (%) 3 (33) 5 (50) 0    
ACE inhibitors/AT2 B (%) 4 (44) 3 (30) 0    
Body weight (kg) 89.72 ± 7.10 97.9 ± 5.76 75.62 ± 4.24 0.38 0.10 0.006
BMI (Kg/m²) 29.26 ± 1.76 32.22 ± 1.84 24.4 ± 0.93 0.27 0.02 0.002
Systolic BP (mm Hg) 142.4 ± 5.09 143.4 ± 5.12   0.90   
Diastolic BP (mm Hg) 71.4 ± 2.59 70.5 ± 4.67   0.87   
Heart rate (beats/min) 67.1 ± 2.16 69.4 ± 3.31   0.58   
Fasting glucose (mmol/L) 8.76 ± 0.78 8.54 ± 1.11 5.2 ± 0.17    
Fasting insulin (μU/l) 10.20 ± 3.20 10.82 ± 2.14     
Hb A1c (%) 7.6 ± 0.59 7.29 ± 0.42 5.24 ± 0.10 0.67 0.0004 0.0002
Total Cholesterol (mmol/L) 4.12 ± 0.28 3.93 ± 0.25 4.5 ± 0.29 0.62 0.36 0.15
LDL (mmol/L) 2.29 ± 0.31 2.25 ± 0.27 2.70 ± 0.26 0.93 0.29 0.22
HDL (mmol/L) 1.19 ± 0.06 1.09 ± 0.10 1.40 ± 0.14 0.42 0.19 0.09
TG (mmol/L) 1.41 ± 0.27 1.33 ± 0.26 0.90 ± 0.17 0.83 0.12 0.18
CRP (mmol/L) 3.00 ± 0.44 6.80 ± 2.38 2.00 ± 0.58 0.15 0.10 0.05
  1. * Oral hypoglycaemic: Included patients taking both metformin and sulfonylurea
  2. Abbreviations:T2DM: Patients with Type 2 Diabetes; M/F: Male/Female; ACE inhibitors: Angiotensin Converting Enzyme inhibitors; AT2B: Angiotensin 2 Blockers; BMI: Body Mass Index, BP: Blood Pressure; Hb A1c: Glycosylated Hemoglobin A1c; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; TG: TriGlyceride; CRP: C-Reactive Protein.